• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

AXON Neuroscience - Articles and news items


AXON Neuroscience’s vaccine designed to halt Alzheimer’s finishes Phase 1 clinical trial

Industry news / 8 July 2015 / Victoria White

AXON Neuronscience’s vaccine intended to be a disease modifying drug for Alzheimer’s disease patients has passed a Phase 1 safety trial…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +